Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 180 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Follow-Up Questions
BPMUF の株価パフォーマンスは？
BPMUF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Basilea Pharmaceutica AG Allschwil の主な事業テーマや業界は？
Basilea Pharmaceutica AG Allschwil は Biotechnology 業界、セクターは Health Care に属しています。
Basilea Pharmaceutica AG Allschwil の時価総額はいくらですか？
Basilea Pharmaceutica AG Allschwil の現在の時価総額は $NaN です。
Basilea Pharmaceutica AG Allschwil は、買い、売り、ホールドのどれですか？
